Cited by Neurexin-3α-associated autoimmune encephalitis with intracranial diffuse large B lymphoma diagnosed on FDG and TSPO PET/MRI

Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH–Wild-Type Glioblastoma DOI

Nathalie L. Albert,

Debie V. Nelwan,

Daniel F. Fleischmann

et al.

Journal of Nuclear Medicine, Journal Year: 2023, Volume and Issue: 64(10), P. 1519 - 1525

Published: Aug. 3, 2023

The 18-kDa translocator protein (TSPO) is gaining recognition as a relevant target in glioblastoma imaging. However, data on the potential prognostic value of TSPO PET imaging are lacking. Therefore, we investigated association results with survival outcome homogeneous cohort patients. Methods: Patients were included who had newly diagnosed, histologically confirmed isocitrate dehydrogenase (IDH)-wild-type available before either normofractionated radiotherapy combined temozolomide or hypofractionated radiotherapy. SUVmax PET, binding affinity status, tumor volumes MRI, and further clinical data, such O6-alkylguanine DNA methyltransferase (MGMT) telomerase reverse transcriptase (TERT) gene promoter mutation correlated patient survival. Results: Forty-five patients (median age, 63.3 y) included. Median was 2.2 (range, 1.0-4.7). A signal associated survival: High uptake intensity (SUVmax > 2.2) related to significantly shorter overall (OS; 8.3 vs. 17.8 mo, P = 0.037). Besides SUVmax, factors for OS age (P 0.046), MGMT methylation status 0.032), T2-weighted MRI volume 0.031). In multivariate analysis, remained an independent factor 0.023), hazard ratio 2.212 (95% CI, 1.115-4.386) death cases high 2.2). Conclusion: diagnosed IDH-wild-type glioblastoma. seems add insights beyond established parameters might serve informative tool clinicians make predictions

Language: Английский

Citations

TSPO PET signal using [18F]GE180 is associated with survival in recurrent gliomas DOI

Stefanie Quach, Adrien Holzgreve, Lena Kaiser

et al.

European Journal of Nuclear Medicine and Molecular Imaging, Journal Year: 2022, Volume and Issue: 50(3), P. 859 - 869

Published: Nov. 4, 2022

Glioma patients, especially recurrent glioma, suffer from a poor prognosis. While advances to classify glioma on molecular level improved prognostication at initial diagnosis, markers prognosticate survival in the situation are still needed. As 18 kDa translocator protein (TSPO) was previously reported be associated with aggressive histopathological features, we correlated TSPO positron emission tomography (PET) signal using [18F]GE180 large cohort of patients their clinical outcome.In PET recurrence, parameters (e.g., SUVmax) as well other imaging features MRI volume, [18F]FET when available) were evaluated together patient characteristics (age, sex, Karnofsky-Performance score) and neuropathological (e.g. WHO 2021 grade, IDH-mutation status). Uni- multivariate Cox regression Kaplan-Meier analyses performed identify prognostic factors for post-recurrence (PRS) time treatment failure (TTF).Eighty-eight consecutive evaluated. tracer uptake tumor grade recurrence (p < 0.05), no significant differences IDH-wild-type versus IDH-mutant tumors. Within subgroup (n = 46), low SUVmax (median split, ≤ 1.60) had significantly longer PRS 41.6 vs. 25.3 months, p 0.031) TTF (32.2 vs 8.7 0.001). Also among glioblastoma 42), (≤ 1.89) not reached 8.2 0.002). remained an independent factor analysis including CNS IDH status, age. Tumor volume defined by or contrast-enhanced weakly uptake. Treatment regimen did differ median split subgroups.Our data suggest that can help even homogeneous subgroups may therefore serve valuable non-invasive biomarker individualized management.

Language: Английский

Citations

Translocator protein (18kDA) (TSPO) marks mesenchymal glioblastoma cell populations characterized by elevated numbers of tumor-associated macrophages DOI

Lorraine Weidner,

Julia Lorenz, Stefanie Quach

et al.

Acta Neuropathologica Communications, Journal Year: 2023, Volume and Issue: 11(1)

Published: Sept. 11, 2023

Abstract TSPO is a promising novel tracer target for positron-emission tomography (PET) imaging of brain tumors. However, due to the heterogeneity cell populations that contribute TSPO-PET signal, interpretation may be challenging. We therefore evaluated enrichment/expression in connection with its underlying histopathological and molecular features gliomas. analyzed expression regulatory mechanisms large silico datasets by performing direct bisulfite sequencing promotor. In glioblastoma tissue samples our study cohort, we dissected association enrichment protein labeling lineage markers immunohistochemistry fluorescence multiplex stains. Furthermore, identified relevant TSPO-associated signaling pathways RNA sequencing. found associated prognostically unfavorable glioma phenotypes promotor hypermethylation linked IDH mutation. Careful histological analysis revealed correlates signal expressed diverse populations. While tumor core areas are major contributor overall signals rim mainly driven CD68-positive microglia/macrophages. Molecularly, high marks subpopulations characterized an mesenchymal gene sets higher amounts tumor-associated macrophages. conclusion, improves understanding as marker gliomas unveiling IDH-dependent differences expression/regulation, regional PET functional implications terms immune interactions.

Language: Английский

Citations

New Radiopharmaceuticals for Brain Tumors Imaging DOI

Adrien Holzgreve, Nathalie L. Albert

Published: Jan. 1, 2024

Language: Английский

Citations

The Traumatic Inoculation Process Affects TSPO Radioligand Uptake in Experimental Orthotopic Glioblastoma DOI

Lukas Gold,

Enio Barci, Matthias Brendel

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(1), P. 188 - 188

Published: Jan. 15, 2024

The translocator protein (TSPO) has been proven to have great potential as a target for the positron emission tomography (PET) imaging of glioblastoma. However, there is an ongoing debate about various sources TSPO PET signal. This work investigates impact inoculation-driven immune response on signal in experimental orthotopic

Language: Английский

Citations

Things are because we see them (O. Wilde): new radiopharmaceuticals for nuclear medicine imaging DOI